Book chapter
Percent Free PSA
Prostate Cancer Diagnosis, pp.51-60
Current Clinical Urology, Humana Press
10/17/2012
DOI: 10.1007/978-1-62703-188-2_5
Abstract
The introduction of PSA in 1987 (Stamey et al. N Engl J Med 317(15):909–16, 1987) as a serum marker for prostate cancer and its subsequent development as a screening test for early detection (Catalona et al. N Engl J Med 324(17):1156–61, 1991) dramatically altered the diagnosis and management of this disease. PSA correlated directly with prostate cancer risk and, therefore, was a relatively sensitive test to identify men at risk. However, it became rapidly apparent that PSA had a limited specificity. Numerous nonmalignant processes, such as benign prostatic hyperplasia (BPH) and infection, also resulted in PSA elevations (Nadler et al. J Urol 154(2 Pt 1):407–13, 1995).
Details
- Title: Subtitle
- Percent Free PSA
- Creators
- Kenneth G Nepple - Division of Urologic Surgery, Washington University School of Medicine, St. Louis, USAGurdarshan S Sandhu - Division of Urologic Surgery, Washington University School of Medicine, St. Louis, USAAdam S Kibel - Division of Urology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Boston, USA
- Resource Type
- Book chapter
- Publication Details
- Prostate Cancer Diagnosis, pp.51-60
- Series
- Current Clinical Urology
- DOI
- 10.1007/978-1-62703-188-2_5
- Publisher
- Humana Press; Totowa, NJ
- Language
- English
- Date published
- 10/17/2012
- Academic Unit
- Urology
- Record Identifier
- 9984051891202771
Metrics
12 Record Views